Updated Analysis of a Phase 1, Open-Label Study of LCAR-B38M, a Chimeric Antigen Receptor T Cell Therapy Directed Against B-Cell Maturation Antigen, in Patients with Relapsed/Refractory Multiple Myeloma

被引：27

作者：

Zhao, Wan-Hong ^{[1
]}

Liu, Jie ^{[1
]}

Wang, Bai-Yan ^{[1
]}

Chen, Yin-Xia ^{[1
]}

Cao, Xing-Mei ^{[1
]}

Yang, Yun ^{[1
]}

Zhang, Yi-Lin ^{[1
]}

Wang, Fang-Xia ^{[2
]}

Zhang, Peng-Yu ^{[1
]}

Lei, Bo ^{[1
]}

Gu, Liu-Fang ^{[1
]}

Wang, Jian-Li ^{[1
]}

Yang, Nan ^{[1
]}

Zhang, Ru ^{[1
]}

Zhang, Hui ^{[1
]}

Shen, Ying ^{[1
]}

Bai, Ju ^{[1
]}

Xu, Yan ^{[1
]}

Wang, Xu-Geng ^{[1
]}

Zhang, Rui-Li ^{[1
]}

Wei, Li-Li ^{[1
]}

Li, Zong-Fang ^{[3
]}

Li, Zhen-Zhen ^{[3
]}

Geng, Yan ^{[4
]}

He, Qian ^{[4
]}

Zhuang, Qiu-Chuan ^{[5
]}

Fan, Frank Xiao-Hu ^{[5
]}

He, Ai-Li ^{[1
,3
]}

Zhang, Wang-Gang ^{[1
]}

机构：

[1] Xi An Jiao Tong Univ, Dept Hematol, Affiliated Hosp 2, Xian, Shaanxi, Peoples R China

[2] Xi An Jiao Tong Univ, Affiliated Hosp 2, Xian, Shaanxi, Peoples R China

[3] Xi An Jiao Tong Univ, Natl Local Joint Engn Res Ctr Biodiagnost & Bioth, Affiliated Hosp 2, Xian, Shaanxi, Peoples R China

[4] Xi An Jiao Tong Univ, Dept Clin Lab, Affiliated Hosp 2, Xian, Shaanxi, Peoples R China

[5] Nanjing Legend Biotech, Nanjing, Jiangsu, Peoples R China

来源：

BLOOD | 2018年 / 132卷

关键词：

D O I：

10.1182/blood-2018-99-110548

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

955

引用

页数：4

共 50 条

[41] Current advances in chimeric antigen receptor T-cell therapy for refractory/relapsed multiple myeloma
Huang, He
uW, Heng-wei
Hu, Yong-xian
JOURNAL OF ZHEJIANG UNIVERSITY-SCIENCE B, 2020, 21 (01): : 29 - 41
[42] Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T cell Function against Multiple Myeloma Is Enhanced in the Presence of Lenalidomide
Works, Melissa
Soni, Neha
Hauskins, Collin
Sierra, Catherine
Baturevych, Alex
Jones, Jon C.
Curtis, Wendy
Carlson, Patrick
Johnstone, Timothy G.
Kugler, David
Hause, Ronald J.
Jiang, Yue
Wimberly, Lindsey
Clouser, Christopher R.
Jessup, Heidi K.
Sather, Blythe
Salmon, Ruth A.
Ports, Michael O.
MOLECULAR CANCER THERAPEUTICS, 2019, 18 (12) : 2246 - 2257
[43] Targeting B-cell maturation antigen for treatment and monitoring of relapsed/refractory multiple myeloma patients: a comprehensive review
Yashar, David
Regidor, Bernard
Goldwater, Marissa-Skye
Bujarski, Sean
Del Dosso, Ashley
Berenson, James R.
THERAPEUTIC ADVANCES IN HEMATOLOGY, 2024, 15
[44] Pathogen-Specific Humoral Immunity and Infections in B Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy Recipients with Multiple Myeloma
Josyula, Srirama
Pont, Margot J.
Dasgupta, Sayan
Song, Xiaoling
Thomas, Sushma
Pepper, Gregory
Keane-Candib, Jacob
Stevens-Ayers, Terry L.
Ochs, Hans D.
Boeckh, Michael J.
Riddell, Stanley R.
Cowan, Andrew J.
Krantz, Elizabeth M.
Green, Damian J.
Hill, Joshua A.
TRANSPLANTATION AND CELLULAR THERAPY, 2022, 28 (06): : 304.e1 - 304.e9
[45] Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2)
Zhao, Wan-Hong
Wang, Bai-Yan
Chen, Li-Juan
Fu, Wei-Jun
Xu, Jie
Liu, Jie
Jin, Shi-Wei
Chen, Yin-Xia
Cao, Xing-Mei
Yang, Yun
Zhang, Yi-Lin
Wang, Fang-Xia
Zhang, Peng-Yu
Lei, Bo
Gu, Liu-Fang
Wang, Jian-Li
Zhang, Hui
Bai, Ju
Xu, Yan
Zhu, Han
Du, Juan
Jiang, Hua
Fan, Xiao-Hu
Li, Jian-Yong
Hou, Jian
Chen, Zhu
Zhang, Wang-Gang
Mi, Jian-Qing
Chen, Sai-Juan
He, Ai-Li
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2022, 15 (01)
[46] CARTITUDE-2 Cohort B: Efficacy and Safety of Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T-Cell Therapy Directed Against B-Cell Maturation Antigen, in Patients With Multiple Myeloma and Early Relapse After Initial Treatment
Van de Donk, Niels W. C. J.
Delforge, Michel
Agha, Mounzer
Cohen, Adam D.
Cohen, Yael C.
Hillengass, Jens
Anguille, Sebastien
Kerre, Tessa
Roeloffzen, Wilfried
Schecter, Jordan M.
De Braganca, Kevin C.
Varsos, Helen
Wang, Liwei
Vogel, Martin
Zudaire, Enrique
Corsale, Christina
Akram, Muhammad
Geng, Dong
Nesheiwat, Tonia
Pacaud, Lida
Sonneveld, Pieter
Zweegman, Sonja
BRITISH JOURNAL OF HAEMATOLOGY, 2022, 197 : 118 - 119
[47] Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2)
Wan-Hong Zhao
Bai-Yan Wang
Li-Juan Chen
Wei-Jun Fu
Jie Xu
Jie Liu
Shi-Wei Jin
Yin-Xia Chen
Xing-Mei Cao
Yun Yang
Yi-Lin Zhang
Fang-Xia Wang
Peng-Yu Zhang
Bo Lei
Liu-Fang Gu
Jian-Li Wang
Hui Zhang
Ju Bai
Yan Xu
Han Zhu
Juan Du
Hua Jiang
Xiao-Hu Fan
Jian-Yong Li
Jian Hou
Zhu Chen
Wang-Gang Zhang
Jian-Qing Mi
Sai-Juan Chen
Ai-Li He
Journal of Hematology & Oncology, 15
[48] Impact of Frailty on Outcomes after Chimeric Antigen Receptor T Cell Therapy for Patients with Relapsed/Refractory Multiple Myeloma
Davis, James A.
Dima, Danai
Ahmed, Nausheen
Dejarnette, Shaun
McGuirk, Joseph
Jia, Xuefei
Raza, Shahzad
Khouri, Jack
Valent, Jason
Anwer, Faiz
Abdallah, Al-Ola
Hashmi, Hamza
TRANSPLANTATION AND CELLULAR THERAPY, 2024, 30 (03): : 298 - 305
[49] Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma
Ernst, Moritz
Oeser, Annika
Besiroglu, Burcu
Caro-Valenzuela, Julia
Aziz, Mohamed Abd El
Monsef, Ina
Borchmann, Peter
Estcourt, Lise J.
Skoetz, Nicole
Goldkuhle, Marius
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2021, (09):
[50] B-Cell Maturation Antigen (BCMA) as a Target for New Drug Development in Relapsed and/or Refractory Multiple Myeloma
Abramson, Hanley N.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (15) : 1 - 24

← 1 2 3 4 5 →